Just saw Jefferies threw a Buy rating on SpyGlass Pharma (SGP) back in early March. Interesting timing for a pharma stock getting analyst love. The thing that caught my eye though - institutional interest is basically non-existent. Only 1 fund has a position, and they're holding like 0K shares. Pretty wild for a company getting coverage from a major bank. SpyGlass apparently has Huntington National Bank on the shareholder list, but again, minimal holdings. Makes you wonder if this is a potential opportunity being overlooked or if there's a reason institutions are sleeping on it. The average fund weight is basically 0.00%, so SpyGlass isn't on anyone's radar yet. Could be early stage, could be a red flag - hard to say. Anyway, if you're into pharma plays, might be worth digging into what Jefferies actually sees here.